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1. Introduction
The importance of gene therapy strategies for the treatment of malignancies is highlighted by
the fact that there are (at the time of writing) 823 cancer gene therapy clinical trials world‐
wide that are actively, or have yet to begin recruiting patients (www.clinicaltrials.gov - ac‐
cessed November 2012).  The potential  of the delivery of genetic material  for therapeutic
purposes has long been recognised, but to this point, has yet to be successfully translated.
Strategies that have proved promising in the in vitro setting have stumbled when exposed to
the complexities of the in vivo environment. Classically involving the delivery of plasmid
DNA (pDNA) that encodes a therapeutic protein product,  the field of  gene therapy has
evolved to encompass not only delivery of therapeutic DNA, but also micro- (miRNA), short
hairpin- (shRNA) and small interfering RNAs (siRNA) and oligodeoxynucleotides (ODNs)
[1]. Despite the evolution of the technology for altering the genotype of target cells and tis‐
sues, the problem of overcoming the biological barriers that limit the efficacies of these tech‐
nologies remains. These barriers exist at both systemic and local levels. To date, the only
approved nucleic acid-based treatments for clinical use are an antisense ODN for the treat‐
ment of cytomegalovirus retinitis [2], and pegaptanib sodium (Macugen), an RNA aptamer
targeted against VEGF-165 and used to treat age-related macular degeneration [3]. This chap‐
ter will focus on the biological barriers faced by non-viral vectors for gene therapy, strategies
that have been employed to overcome these barriers, and will conclude by documenting the
state of the art technologies being used to propel non-viral gene therapies forward.
1.1. Non-viral gene therapy
Delivery of genetic material for therapeutic use from virus-like particles has received consid‐
erable attention, and has generated extensive knowledge. The molecular evolution of viruses
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over the aeons has produced DNA-delivering organisms of incomparable efficiency. The use
of ‘gutted’ viruses that lack virulence properties and replicative capacity is the most efficient
method of genetic material delivery [4], and modified viruses have been used extensively in
gene therapy; commonly employed viruses include adenovirus, retrovirus, vaccinia virus and
herpes simplex virus [5]. The allure of viral gene therapy was hindered however, when a clin‐
ical trial patient died four days after receiving adenoviral therapy for treatment of ornithine
transcarbamylase deficiency [6]. The negative press that this generated, along with other dis‐
advantages of viral gene therapy (including generation of immune response, possibility of
proto-oncogene activation, production costs, and limitations in deliverable gene size) have ne‐
cessitated the generation of alternative gene therapy strategies [7].
Despite some success when naked DNA has been delivered in vivo (naked pDNA has been
effectively delivered to the liver in mice and rats [8] by tail vein injection), pDNA for gene
therapy is conventionally delivered complexed with materials with suitable physical charac‐
teristics. pDNA’s hydrophilicity and anionic nature impair the uncomplexed molecule’s
passage through the lipophilic plasma membrane [1,9,10]. Non-viral gene therapy strategies
usually involve wrapping of the nucleic acid to be delivered in a protective envelope that
neutralises the negative charge of the DNA. A range of compounds has been used to envel‐
op pDNA, including cationic lipids, polymers and peptides.
Cationic lipids were among the first compounds complexed with pDNA for non-viral gene
delivery. Felgner reported that N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium
chloride (DOTMA) formed lipid-DNA complexes based on the interaction between the posi‐
tively charged lipid and the negatively charged phosphates of the DNA. The lipoplexes so-
formed were capable of delivering DNA to cells in vitro [11]. Numerous cationic lipids have
since been reported to neutralise, condense and encapsulate pDNA, including dioctadecyla‐
midoglycylspermine (DOGS) [12],[1,2-bis(oleoyloxy)-3-(trimethylammonio)propane] (DO‐
TAP) [13] and 3β[N-(N′, N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) [14].
Variations on a theme, these lipids behave similarly to innate biological lipids [15]. The ad‐
dition of co-lipids such as cholesterol and dioleoylphosphatidylethanolamine (DOPE) can
improve transfection efficiency [16]. Recent developments in the field have seen a 1-palmito‐
yl-2-oleoyl-sn-glycero-3-ethylphosphocholine (EPOPC):cholesterol liposome with folate
electrostatically-associated used to deliver HSV-tk suicide gene therapy to SCC-VII xeno‐
grafts, which resulted in considerable tumour growth delay [17]. In a magnetofection meth‐
od, intravenous delivery of superparamagnetic iron oxide lipid nanoparticles in
combination with an Nd-Fe-B magnet placed externally in the tumour locality resulted in
improved IGF-1R shRNA delivery to A549 xenografts [18].
Cationic polymers have been used to condense and deliver genetic material, including
poly(l-lysine) (PLL), polyethylenimine (PEI), chitosan and polyamidoamine (PAMAM) [7].
PLL incorporated into a spider silk-based nanoparticle with a tumour-homing peptide was
recently reported to deliver a luciferase plasmid to MDA-MB-231 xenografts following intra‐
venous administration [19]. A novel triblockpoly(amido amine)-poly(ethylene glycol)-poly-
l-lysine (PAMAM-PEG-PLL) nanocarrier successfully delivered Bcl-2 siRNA and elicited
knockdown of the same in A2780 ovarian carcinoma cells in vitro [20]. Heparin-PEI nanogels
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were used to reintroduce heparin sulphate 6-O-endosulfatase 1 (HSulf-1) to ovarian SKOV-3
xenografts, which resulted in anti-angiogenesis, induction of apoptosis and suppression of
cell proliferation [21], while a PEI-poly(hydroxyethyl glutamine) (PEI-PHEG) copolymer
successfully delivered pGL3 pDNA by intratumoural administration to Lewis Lung Carci‐
noma xenografts in C57BL/6 mice [22].
Cationic peptides that are capable of neutralising, condensing and wrapping pDNA have al‐
so been used as non-viral delivery vehicles [23]. These cell-permeating peptides were de‐
signed to interact with cell membranes similarly to viral fusion proteins. GALA, a synthetic
peptide designed to interact with lipid bilayers at an acidic pH, was observed to aid in the
delivery of DNA to cells [23]. A derivative, termed KALA, through presence of positively
charged lysine residues, is capable of condensing and delivering DNA unaided [24], and im‐
proved gene delivery ten-fold in hepatoma [25] and also in HEK293T and HepG2 cells [26].
The cell-penetrating peptide TAT and fusogenic peptide HA2 were used to improve pDNA
delivery by gelatin-silica nanoparticles [27]. Recent developments in the field have seen the
development of multi-domain peptidic biomimetic vectors tailored to overcome the various
biological barriers that gene delivery vehicles encounter in vivo, including degradation by
serum nucleases, endosomal entrapment and nuclear localization. One such designer biomi‐
metic vector was used to deliver tumour-related apoptosis inducing ligand (TRAIL) [28] and
inducible nitric oxide synthase (iNOS) pDNA to ZR-75-1 breast cancer cells in vitro [29].
Non-viral strategies for gene therapy have several advantages over traditional viral ap‐
proaches, including reduced cost and ease of large-scale production, as well as avoidance of
the virulence commonly associated with viral delivery. However, non-viral gene delivery
systems suffer from lower potency of transfection ability, resultant of lower ability to tra‐
verse the various obstacles faced upon administration [7].
2. Extracellular barriers to gene delivery
2.1. The skin
The most fundamental barrier that the human body possesses is its skin. The stratum cor‐
neum is the skin’s outermost layer, and provides an imposing barrier to gene delivery [30];
the densely packed cornified cells of this layer protect the body from a range of foreign ma‐
terial. The skin is not a commonly used route for gene therapy approaches, but it is an at‐
tractive route for local targeting of dermatological ailments [31]. However, skin nucleases,
and in particular DNAse 2, active at the skin and in the stratum corneum, degrade topically-
applied nucleic acids [32]. An appropriate and potent delivery mechanism could open the
door to gene therapy strategies for the treatment of skin conditions and malignancies, in‐
cluding xeroderma pigmentosum (a cancer-linked disorder that has shown promise in pre‐
clinical gene therapy approaches [33]), when replacement of the defective XPC gene is in
keratinocytes would be therapeutically beneficial [34].
Introduction  of  micron-sized pores  to  the  skin  using  minimally-invasive  silicone  micro‐
needles allowed for the delivery of  a 'non-viral  gene vector-mimicking'  charged fluores‐
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cent  nanoparticle  [35,36].  A needle-free  injection device  successfully  delivered luciferase
pDNA to porcine skin, resulting in higher protein expression than conventional hypoder‐
mic  needle  administration [37],  while  subcutaneous melanoma xenografts  were targeted
for  gene  therapy  using  a  hybrid  electro-microneedle;  delivery  of  20  µg  interleukin-12
pDNA to the skin, followed by eight 50 ms pulses delivering 70V/0.5 cm from the elec‐
trode to improve transfection resulted in a significant improvement in survival of tumour-
bearing mice [38].  Most recently, researchers from Northwestern University reported the
generation  of  siRNA-carrying  nanoparticles  (spherical  nucleic  acid  nanoparticle  conju‐
gates  (SNA-NCs))  that  are  capable  of  penetrating  nude  mouse  and human skin,  whilst
maintaining their RNA interference potential [36]. The nanoparticles comprise gold cores
surrounded by a dense shell of highly oriented, covalently immobilised siRNA and could
be delivered topically, avoiding the need for disruption of the skin. As the skin is unmo‐
lested,  the  authors  propose  that  the  miniscule  nature  of  the  SNA-NCs  permit  dermal
crossing, a theory that is currently under investigation.
2.2. Barriers to systemic gene therapies
Needle-administered systemic therapeutics bypass the skin, but encounter further extracel‐
lular barriers before reaching their site of action. The various administration routes (intra-
venous, -muscular, -ocular, -nasal) present their own unique impediments to nucleic acid
delivery. Intravenously- [39] and intramuscularly-administered [40] therapies are subject to
nuclease degradation from the point of entry. Conversely, naked uncomplexed anti-respira‐
tory syncytial virus (RSV) siRNA was almost as effective as that complexed with TransIT-
TKO transfection reagent when nasally-administered in mice [41], suggesting that nasally-
administered gene therapies may not be as prone to nuclease insult. The compartmental
nature of the eye, and ease of access to it simplifies avoidance of similar barriers in ocular
gene therapy delivery [42]. pDNA complexed with poly(d,l-lactic-co-glycolic) acid (PLGA)
and dimethyldioctadecylammonium bromide (DDAB) produced nanoparticles capable of
traversing one of the most inhospitable of barriers, the gastric mucus [43]. For simplicity,
this chapter will focus on the barriers faced by intravenously delivered therapies, as this
route has the potential to target almost all tissues of the body.
The complexing of DNA into lipo- or polyplex nanoparticles in non-viral delivery can effec‐
tively protect the pDNA from nuclease degradation [44] (although, paradoxically, cationic
and anionic lipoplexes can hinder pDNA delivery by electroporation [45]). Whilst in the cir‐
culation, however, non-viral agents can be subject to non-specific binding by serum pro‐
teins, which can result in aggregation or dissociation of nanoparticles, resultant of the
generally positive charges of the nanoparticles and the negative charge of circulatory pro‐
teins [1]. Positive charge is essential to ensure interaction of the nanoparticle with its target
cell, however the mononuclear phagocytic system (MPS) eliminates foreign hydrophobic
particles from the circulation [7] by opsonisation. The MPS was neutralised in mice by pre-
treatment with polyinosinic acid (a synthetic nucleic acid strand) before therapeutic measles
virus treatment; this led to competitive inhibition of the scavenging of particles by macro‐
phages, and improved virus delivery to and efficacy at SKOV3 xenografts [46]. Aggregation
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of nanoparticles can cause embolization of microvessels, and non delivery of the therapeutic
to target [1].
The differential in ionicity between gene therapy formulation and the extracellular space
poses another obstacle for nanoparticles, which can lead to colloidal instability [44]. The is‐
sue of non-specific interaction between nanoparticles and plasma proteins has been ad‐
dressed by the coupling of hydrophilic molecules to the nanoparticle. The most commonly
employed candidate is poly(ethylene glycol) (PEG), whose anionicity has led to reduced ag‐
gregation and improved transfection ability [47]. PEG has been incorporated into a myriad
of non-viral gene therapy strategies. Recently, polyacridine peptide nanoparticles were PE‐
Gylated and found to persist in the mouse circulation for up to nine hours, compared to
non-PEGylated nanoparticles, which were inactive within five minutes [48], while biode‐
gradable dextran nanogels were PEGylated and analysed for their siRNA delivering prow‐
ess [49]. Particulate gene therapies are also subject to entrapment by the mononuclear
phagocyte system (reticuloendothelial system - RES), when they are captured and held in
the spleen or liver [50], which was responsible for the inactivation of adenoviral vectors that
have been used as viral gene therapeutics [51]. Avoidance of non-specific biomolecular in‐
teraction, referred to as ‘stealth’ [1], is a prerequisite for successful gene delivery. Function‐
alisation of non-viral gene therapies with agents such as PEG to facilitate RES avoidance will
be discussed in subsequent sections.
Assuming a gene therapeutic persists in active form in the circulation and the target tissue is
reached, extravasation from the circulation is imperative. The architecture of normal vascu‐
lature ensures that transport of macromolecules out of the circulation is difficult. One char‐
acteristic of tumour vasculature, however, is its propensity to leakiness, an attribute that can
be exploited by gene therapies. It is unsurprising that siRNA lipoplexes that target RAN
GTPase were delivered more effectively, and evoked more impressive anti-tumour effects in
highly vascularised xenografts than in xenografts with poorer vascularity [52]. The leaky
vessel phenomenon, known as the enhanced permeability and retention (EPR) effect, has
been utilised to enable the delivery of pDNA-containing particles in various malignancies
[53]. The utilization of EPR will be further discussed below. The angiogenic tumour vascula‐
ture was itself targeted in a murine dorsal air sac assay; siRNA targeting Ago2 was com‐
plexed into cationic liposomes and intravenously administered. The authors successfully
delivered the interfering RNA to the angiogenic vessels, and reported tumour regression,
presumed to be resultant of anti-angiogenesis in their model [54].
Perhaps the most intimidating vascular obstacle that a gene therapy can face is the blood-
brain barrier, where tight junctions between endothelial cells of the capillaries limit the pas‐
sage of molecules much more than at other capillary sites in the body. One of the most
exciting techniques available to the gene therapy researcher is the use of ultrasound-target‐
ed microbubble destruction (UTMD); nucleic acid contained within a gas-filled microbubble
is administered, before exposure to ultrasonic waves at a frequency that exceeds the reso‐
nance frequency of the microbubbles, causing their destruction and leading to increased ca‐
pillary and cell membrane permeability [55]. This technology was used to deliver pDNA for
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the green fluorescent protein (GFP) reporter gene across the mouse blood-brain barrier [56],
and presents new possibilities for overcoming this most daunting of circulatory barriers.
2.3. Cellular barriers to gene delivery
2.3.1. The cell membrane and endocytosis
Specific targeting of gene vectors to ensure delivery to the target tissue will be discussed in a
subsequent section. The nanoparticle’s nucleic acid cargo determines the site to which deliv‐
ery is required; plasmid DNA must be delivered to the nucleus to affect transcription, while
siRNA need only reach the cytoplasm to interfere with translation [57]. The most elemental
impediment to entry into the animal cell is the lipid bilayer membrane. The cell membrane
can be breached using physical means in certain circumstances to allow delivery of naked
pDNA. These methods include electroporation (local destabilization of the cell membrane
using an electric pulse), sonoporation (membrane destabilization using ultrasound) or laser
irradiation (introduction of transient pores in the membrane using a lens-focussed laser
beam). The application of these methods is limited, however, by inaccessibility to most tis‐
sues [58].
Condensation and neutralization of nucleic acids into nanoparticles abrogates the two fun‐
damental properties of pDNA that preclude its cellular entry, namely its large size and neg‐
ative charge [1]. Particles of excessive size can aggregate and cause embolization of narrow
capillaries, as mentioned above. Nanoparticles for gene delivery tend to be sub-200 nm for
this reason. However, in vivo delivery of fluorescently labelled liposomes of up to 400 nm
diameter has been reported [59]. Particle size also appears to dictate the pathway that per‐
forms internalization of complexes; 200 nm particles have entered cells by clathrin-depend‐
ent routes, 300 nm particles by caveolae-mediated pathways [7]. Optimization of the net
charge (or zeta/ζ potential) of delivery vehicle/nucleic acid complex of lipid/polymer/
peptide and pDNA complexes is achieved by the electrostatic interaction between the nega‐
tively charged phosphate residues present in the pDNA and the positively charged nitrogen
in the vehicle. The net charge of the resultant particle can be increased by increasing the ve‐
hicle (nitrogen) to pDNA (phosphate) ratio (known as N:P ratio) [1]. The negative charge of
serum proteins can thwart the therapeutic potential of nanoparticles; this can be overcome
by increasing the N:P ratio of complexes above that sufficient to condense the pDNA. Alter‐
ing the net charge of the nanoparticles can significantly alter the array of plasma proteins
that interact with the particles. Similar liposomal particles with charges of -9.0, -11.4 and
-27.4 were incubated with human plasma, and the interacting proteins were identified; 117
proteins were found bound to particles of all three charges, while 12, 6 and 15 plasma pro‐
teins interacted uniquely with the three particle charge types respectively [60]. Kim and co-
workers reported that hyperbranched polysiloxysilane nanoparticles with a moderate
positive charge (46 mV) were more efficient gene delivery agents than analogous particles
with a high positive charge (64 mV) [61]. Clearly, nanoparticle size and charge are parame‐
ters that require optimization for appropriate cell membrane breaching. Phosphonium-
based vectors (as opposed to nitrogen-based) are also being explored for their gene delivery
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potential; preliminary studies have revealed that phosphonium-based vectors condensed
DNA at lower charge ratios than corresponding nitrogen-based vectors [62].
Figure 1. Summary of the extra- and intracellular barriers faced by non-viral gene therapies following systematic deliv‐
ery. Based on [1].
Electrostatic interaction between the cationic nanoparticle and the anionic cell membrane
that facilitate association between the cell and nanoparticle was assumed to result in endo‐
cytosis of the nanoparticle, although the machinery of internalization appears to be material-
and cell type-dependent. Endocytotic access to cells is by pinocytosis in the majority of
cases, rather than by phagocytosis [9]. A mechanism of endocytosis was clarified by Payne
and colleagues, who followed the intracellular trafficking of PEI- and Lipofectamine™-com‐
plexed nucleic acids in mammalian cells, and reported that endocytosis relied upon cell sur‐
face heparin sulphate proteoglycans (HSPG) and was dependent on dynamin- and flotillin,
rather than clathrin- and caveolin-dependent mechanisms [63]. On the other hand, nanopar‐
ticles formed from pDNA complexed with PEG-CK30 were endocytosed after interaction
with cell surface nucleolin, a process that was reliant on the activity of lipid rafts [64]. A re‐
cent study reported by a team at the University of Groningen very elegantly showed lasso‐
ing of PEI- and Lipofectamine™-complexed pDNA by syndecan- and actin-rich filaments of
HeLa cells, presumed to be filopodia and retraction fibers; the nanoparticles then ‘surf’
along the filopodia, or the filopodia are retracted toward the cell body, thereby facilitating
HSPG-mediated endocytosis [65].
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2.3.2. Endosomal escape
The result of endocytic cellular entry is endosomal entrapment. Endosomes are a range of
membrane-bound organelles that include early, late and recycling endosomes that are re‐
sponsible for the short-term storage and sorting of endocytosed materials, including macro‐
molecules and pathogens (including viruses). Once material is endocytosed, it is either
evicted from the cell by the recycling endosome, or the complex process of endosome matu‐
ration ensues, late endosomes fuse with lysosomes, and active degradation of endosome car‐
goes occurs [66]. Macromolecules that are unable to escape the endosome are bound for
lysosomal degradation.
The mechanism of endosomal escape by non-viral vectors is dependent on the complexing
material used. Cationic lipids appear to interact with the anionic endosomal membrane, re‐
sulting in ion pair formation and consequent transformation to inverted hexagonal phase
(HII), causing disruption of the endosomal membrane. Alternatively, an inversion of the en‐
dosomal membrane as a result of electrostatic interactions has been proposed, which would
instigate nucleic acid cargo being deposited in the cytoplasm. When polymeric materials are
used to complex pDNA, the polymers themselves absorb protons in the endosome (proton-
sponge effect), leading to chloride ion influx, increased osmotic pressure and water flow in‐
to the endosome, resulting in endosome rupture [7].
The fusogenic lipid DOPE is frequently used as a co-complexing agent due to its inherent
ability to facilitate endosomal escape; conformational change from lipid bilayer to an invert‐
ed hexagonal structure is triggered by the sub-physiological pH of the endosome, and caus‐
es endosomal membrane disruption and escape of nucleic acid cargo [67]. Viral membrane
proteins have provided inspiration for the non-viral gene delivery researcher. Influenza vi‐
ruses escape the endosome with the help of hemagluttinin A2 (HA2), while the adenoviral
protein, penton, assists adenovirus endosome escape. Glycoprotein H from herpes simplex
virus induced 30-fold improvement of transfection by lipoplexes in human cell lines [68].
Conformational changes of these proteins consequential of the acidic environment in the en‐
dosome facilitate viral particle escape from the endosome; the more hydrophobic conforma‐
tion that they adopt at low pH permits membrane fusion and disruption [1].
Synthetic fusogenic peptides are increasingly being used to improve transfection in non-vi‐
ral systems. The conformational status of GALA is responsive to pH, adopting alpha-helical
status in acidic environments, and in that sense, mimics the endosomal escape route fav‐
oured by viruses [69]. Derivatives of GALA such as GALAdelE3, YALA [70], and KALA [24]
have all shown promise as endosome escaping agents. Similarly, two endosomal escape
peptides, INF7 and H5WYG, improved endosome escape of PEG-based vectors by up to
100-fold [71].
2.3.3. Nuclear envelope penetration
The final obstacle faced by pDNA gene therapies is the nuclear envelope, a barrier punctuat‐
ed with nuclear pores impermeable to molecules greater than 70 kDa, or roughly 10 nm in
diameter [72]. Liposomal fusion with the nuclear membrane that facilitates direct cargo
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transfer from vector to nucleus has been reported [73]. Mitotic division temporarily disrupts
the nuclear membrane’s barrier properties, which can allow pDNA transgene entry [9]. The
nuclear pores can be more actively targeted for penetration by the use of nuclear localization
signalling (NLS) peptides or DNA targeting sequences (DTS). NLSs are short clusters of ba‐
sic amino acids (such as lysine) that bind to importins, receptors that facilitate cytoplasm-
nuclear transport [74]. Active transport of macromolecules through nuclear pore complexes
causes expansion of the pores to approximately 30 nm in diameter [75]. The nuclear localiza‐
tion peptide SV40 from Simian virus 40 was used to improve the delivery of luciferase gene-
carrying liposomes to neuroblastoma cells [76], while NLSs from adenovirus E1a, the
transcription factor c-myc, mouse FGF3, and the DNA repair protein PARP have all been
used to guide transgene delivery to the nucleus [74]. Some of the recently employed nuclear
envelope penetration strategies are summarised in Table 1.
3. Evading the immune system
As mentioned previously, although viruses are masters of nucleic acid delivery, alternative
delivery mechanisms are being sought to avoid the pitfalls associated with viral systems.
Fundamentally, viruses remain foreign pathogens, agents that the human body has evolved
to protect itself from. Of the commonly employed viral vectors, adenoviral, adenovirus-as‐
sociated vectors and lentivirus vectors all produce immune responses in mice and humans,
with antibodies often being produced against both the packaging vector as well as the trans‐
gene product. Exposure to viral particles triggers the adaptive immune response. Pinocyto‐
sis of viral particles by immature dendritic cells elicits maturation of the dendritic cells into
mature antigen-presenting cells that present antigens in major histocompatability complexes
(MHCs). Activation of T cells by antigen presentation leads to both the destruction of the
antigen-presenting cells, and the recruitment and activation of B cells, responsible for anti‐
body production [84].
Attempts to avoid provocation of immunologic responses have been made by the viral gene
therapist that include deletion or nullification of viral coding genes and elimination of
pathogenic genes, or use of targeting strategies to ensure avoidance of the immune cells.
Additionally, pharmacological immunosuppression has been used extensively to avoid the
neutralization of various viral gene therapy strategies [85].
3.1. DNA-mediated immune responses
It is generally accepted that non-viral gene therapy strategies elicit fewer immune responses
than their viral counterparts, although certain facets of non-viral complexes mark them as
targets for immune system intervention [86]. An early report into immune responses in‐
duced by non-viral gene therapy revealed cytokine induction (TNFα and IL-1β) by
PEI/DNA complexes; the extent of immune induction was determined by the route of deliv‐
ery, aerosol proving less detrimental than intravenous [87]. In mice, lipoplex administration
evoked complement activation and induction of IFN-γ, TNF-α, IL-6, and IL-12. These effects
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were independent of N:P ratio or the cationic lipid complexed with the pDNA [88]. Al‐
though observed immune responses tend to be dose-dependent, dose reduction to avoid im‐
mune induction consequently also lessens the transfection ability of the complexes, stressing
the narrow therapeutic index of non-viral gene therapies [89].
It is well established that immune responses in non-viral therapies is resultant of the pres‐
ence of unmethylated CpG motifs in the bacterial backbone of the plasmid. In mammals,
roughly 75% of CpG motifs are methylated to 5′-methycytosine, whereas in bacteria they are
usually unmethylated [89]. Recognition of unmethylated CpG motifs by Toll-like receptor 9
on immune cells causes activation of mitogen-activated protein kinases and NF-κB [90]. As
NLS Sequence Summary Result Ref
TAT Ac-GCGYGRKKRRQRRRG-
NH2
PEG-based vector with
DNA binding peptide
Up to 15-fold increase in
CHO cell transfection
[77]
NLS-1
NLS-2
NLS-3
DPKKKRKV
DPKKKRKVDPKKKRKV
DPKKKRKVDPKKKRKV-
DPKKKRKV
Inclusion of NLS peptides
in Lipofectamine
liposomes for transfection
into human and rat
mesenchymal stem cells
Roughly two-, four- and
six-fold enhancement of
luciferase expression
respectively
[78]
I-NLS Iodinated-PKKKRKV Iodinated NLS was
complexed with pDNA
and PEI. Luciferase
transfection was assessed
in MCF-7 breast cancer
cells
130-fold improvement in
transfection compared to
absence of NLS. Iodination
improved nuclear
localization
[79]
Human surfactant
protein C promoter
318 nucleotides PCR
amplified from genomic
DNA
Sequence cloned into
promoterless plasmid and
microinjected into
cytoplasm of MLE-12 cells.
Fluorescent in situ
hybridization revealed
nuclear localization in
25-30% of injected cells
compared to control (0%).
Specific to alveolar type II
epithelial cells
[80]
Triamcinolone
acetonide (TA)
N/A TA was conjugated to PEI
(various molecular
weights) and nuclear
localization determined
Low molecular weight
PEI/TA efficiently targeted
the nucleus
[81]
Dexamethasone N/A Polyplexed (PEI) with
pLuciferase
10 – 100-fold increase in
transfection efficiency
[82]
Trans-
cyclohexane-1,2-
diol
N/A Amphipathic alcohol that
collapses nuclear pore
cores allowing
macromolecule uptake
Improved Lipofectamine
2000-mediated gene
transfection to 293T cells
in vitro, but was not
reproducible in vivo
[83]
Table 1. Recent strategies employed to aid the delivery of non-viral gene therapies to the nucleus.
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well as eliminating an immune response, evidence exists to suggest that removal of unme‐
thylated CpG motifs can increase the duration of transgene expression [91,92]. PEI-based de‐
livery of CpG-rich pDNA was associated with a reduction in lung compliance, while
delivery of CpG-diminished pDNA was not [93]. Furthermore, methylation of CpG motifs
in pDNA largely reversed the immunostimulatory activity of lipoplexes and polyplexes in
C57BL/6 mice [94].
Numerous strategies have been investigated to abrogate immune responses upon non-viral
gene therapy administration. Liu and colleagues encapsulated various anti-inflammatory
agents into DOTAP/pLuciferase liposomes, and termed the resultant complex a ‘safeplex’.
Safeplexes carrying dexamethasone, prednisone, indomethacin, tetrandrine and gliotoxin in‐
hibited TNFα expression compared to that seen in the absence of anti-inflammatory. Impor‐
tantly, the complexing of dexamethasone into the safeplex did not affect the complex’s
ability to deliver its pDNA cargo [89]. Delivery of oligonucleotides to inhibit cytokine
(NFκB) translation using non-viral carriers has also been proposed as a mechanism of coun‐
teracting the host’s immune response to non-viral therapies [95].
Lipid-protamine-DNA complexes (LPDs) were used to deliver a PCR amplicon of the luci‐
ferase gene rather than a bacterial plasmid containing the luciferase gene. Luciferase transla‐
tion was as efficient from the PCR amplicon as from the plasmid when both were
complexed with LPD, but the immune response evoked by the PCR fragment complex was
three-fold less potent than that evoked by the plasmid complex (determined by TNFα and
IL-12 expression) [96].
The immune response can be avoided by the removal of unnecessary bacterial DNA that
contains the immunological  CpG motifs,  bacterial  origin of  replication,  as  well  as  genes
for plasmid antibiotic  resistance that  are not  required for transgene expression.  First  re‐
ported in 1997,  minicircles  are gene delivery vehicles  that  lack prokaryotic  nucleic  acid,
and were produced by the thermo-responsive activity of λ integrase [97]. Minicircles were
more potent reporter gene deliverers than their  parental  pDNA in melanoma and colon
carcinoma cell  lines  by  lipofection  and electroporation  [98].  Minicircles  complexed with
PEI also delivered the GFP gene more potently than similarly complexed pDNA [99]. The
potency of  minicircles has been improved by tethering minicircle  liposomes to the TetR
nuclear targeting device [100].
A further improvement on the immunologically inert minicircles has recently been mooted.
Tightly-wound miniknot vectors are the result of DNA minicircle treatment with DNA top‐
oisomerase II, and are proposed to be more resistant to physical damage (strand breaks) that
can linearise (thereby reducing/removing efficacy) pDNA and minicircles. DNA delivery
methods such as aerosol inhalation, jet-injection, electroporation, particle bombardment and
ultrasound DNA transfer can subject DNA to stresses that might cause damage [101].
3.2. Carrier-mediated immune responses
It is important to note that immune responses to non-viral gene therapy are not solely resul‐
tant of bacterial CpG motifs. An impressive study from Kyoto University highlighted the
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immune responses that can be generated by liposomes. Using CpG-free pDNA in lipoplex‐
es, the authors demonstrated activation of IFNβ, TNFα and IL-6 in macrophages from TLR9
knockout mice. The extent of the immune response (as determined by in vitro cytokine in‐
duction) was dependent on the cationic lipid content of the complex. The reactions elicited
by the cationic lipids can be summarised as Lipofectamine 2000 > Lipofectamine Plus >
DOTMA/DOPE > DOTMA/cholesterol [102]. The inertness of DOTMA/cholesterol as deliv‐
ery vehicle was supported further in vivo, when CpG-free pDNA lipoplexes provoked no
IL-6 or IFNβ induction after intravenous injection in mice [103]. The targeting of nucleic acid
cargoes to specific cells/tissues (to be discussed shortly) could also remedy the immune re‐
sponse by preventing the transfection of non-target cells, and in particular, the antigen-pre‐
senting cells [85].
The continuing evolution of the non-viral gene therapy field has led to the development of
transposon-based delivery strategies, including Sleeping Beauty, Tol2, and piggyBac. These
systems appear to deliver DNA as efficiently as viruses, and provoke extended transgene
product expression, whilst maintaining the low immunogenicity and other risk factors asso‐
ciated with viral gene delivery [104]. It is anticipated that the momentum of non-viral gene
therapy research will lead to the development of vehicles and cargoes that will rival the vi‐
ral gene therapy field.
4. Targeting in non-viral systems
The optimal gene delivery vector will protect its payload from degradation in the circula‐
tion, enable extravasation from the bloodstream, traverse cellular membranes, facilitate en‐
dosomal disruption to deliver the payload to either the cytoplasm, or if necessary, transport
to the nucleus. The optimal vector should also be non-immunogenic, as discussed above.
Design of such vectors obviously presents a huge challenge. Furthermore, for vectors that
accomplish extra- and intracellular barrier and immune system avoidance, there is the add‐
ed layer of complication that targeting presents. Frequently in cancer studies, the payload to
be delivered is a therapeutic designed to over-express a protein or knockdown a gene to
manifest an anti-cancer effect. In order to spare normal tissue damage, widespread toxicity,
and to achieve a clinically viable therapeutic product, targeting has become an essential in
the quest for a perfect vector.
4.1. Enhanced permeation and retention effect
Exploitation of the tumour microenvironment presents an obvious option in the targeting
strategies employed by many delivery systems. The enhanced permeation and retention ef‐
fect (EPR), which was mentioned briefly above, is a phenomenon whereby there is defective
architecture in blood vessels, extensive angiogenesis, increased vascular permeability and
an impaired function of the mononuclear phagocytic system [105-107]. The consequences of
these tumour-specific physiological changes is that macromolecules > 40 kDa selectively
‘leak’ out of the blood vessels and extravasate into the interstitial tumour tissue [108,109].
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Particle size is an important factor for utilizing the EPR effect. Studies have shown that
nanoparticles up to 400 nm in diameter can permeate across tumour vessels [59,110]. How‐
ever, circulation times can also play a key role in successful tumour transduction, with a
minimum of 6 h required for the EPR effect to occur [111]. The EPR effect has been exploited
not only in chemotherapy drug design but also in gene delivery. In one such example, poly‐
glycerolaminne (PG-Amine) dendrimers were complexed with siRNA and delivered intra‐
venously to mice bearing luciferase tagged mammary tumours; after 24 h, there was a 69%
reduction in luciferase activity [112]. The authors also reported that there was clear evidence
of accumulation of the complexes in the tumours but not in any other organs, which can be
attributed to the EPR effect. In order for continuous knockdown of luciferase, it was deter‐
mined that injections would be needed every four days [112].
There are however, a number of problems if the EPR effect is the sole mechanism for target‐
ing in cancer gene therapy. One such problem is tumour size. Tumours that are larger than 1
cm in diameter develop hypoxic regions that are characterised by a lack of blood vessels,
therefore the EPR effect becomes redundant in these resistant regions. Evans blue dye and
albumin were used to generate a synthetic macromolecule delivery of which showed that
although selective, in tumours larger than 3 cm, the dye accumulated solely in the peripher‐
al regions and not in the central core [113]. One method to increase the EPR in solid tumours
is through the use of nitric oxide donors in combination with macromolecular delivery. En‐
dogenous nitric oxide (NO) has an effect on blood flow, angiogenesis and metastatic poten‐
tial [114-116]. From a therapeutic perspective there are conflicting reports as to whether it is
better to enhance or inhibit nitric oxide within tumours [117]. From an enhancement per‐
spective, studies within our own group using iNOS (inducible NO synthase) gene therapy
have shown the cytotoxic and radio-chemo sensitizing affects through the generation of µM
levels of NO [118,119]. The controlled generation of high levels of nitric oxide as the gene
therapy has several anti-cancer advantages, including a genotoxic effect through oxidation,
deamination and alkylation of DNA, reduction of the efficiency of DNA repair proteins such
as Poly ADP Ribose Polymerase, inhibition of the transcription of hypoxia inducible factor
and the anti-apoptotic factor NF-kB which reduces many other pro tumourigenic factors
such as MMP1, 3, 9, VEGF, survivin and BCL2 [120]. Derivatives of NO such as peroxyni‐
trite (ONOO) have also been shown to potentiate the EPR effect. Wu and colleagues showed
that this was also linked to activation of MMPs, which are known to enhance vascular per‐
meability and angiogenesis through the degradation of matrix proteins [121]. One of the
main ways of enhancing the EPR effect is through NO donors, which have been utilised in
combination with chemotherapy drugs. For example nitroglycerin has been delivered with
vinorelbine and cisplatin in patients with non-small cell lung cancer in a randomised phase
II trial. Results showed a response rate of 73% in those patients that received the nitroglycer‐
in plus chemotherapy, compared to 42% in the chemotherapy only arm. The improved ef‐
fects were attributed to the known anti-cancer effects of NO and an improvement in drug
delivery to the tumour tissue, i.e. the EPR effect [122]. With respect to gene therapy, the de‐
livery of the iNOS gene would most certainly enhance the EPR effect in solid tumours al‐
though consideration must be given to the amount of NO generated. As gene expression is
dependent on successful nuclear transport of the plasmid, it would be very difficult to pre‐
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dict and indeed control. With NO gene therapy, it is therefore essential to target the expres‐
sion of the gene to the target tissue to gain the maximum therapeutic benefit.
Another problem in EPR targeting comes about with what is commonly termed the ‘PEG di‐
lemma’. This is essentially a trade-off between circulation time and efficacy of nucleic acid de‐
livery. Many nanoparticles are PEGylated to increase circulation time, avoid clearance by the
reticuloendothelial system (RES) and evade an immune response. As previously stated, if the
EPR effect is to be exploited in solid tumours, a long circulation time is needed and PEG repre‐
sents a possible solution. However, the physiochemical properties of many delivery systems
are altered when PEG is introduced; this is particularly the case when the cargo is nucleic
acids such as siRNA or DNA. In order for nucleic acids to be successful they must be deliv‐
ered to the correct intracellular destination. PEG not only reduces the overall charge of the
nanoparticles, which in turn lowers the cellular uptake, but also impairs disruption of the en‐
dosome. Therefore if PEGylation is to be used to enable EPR targeting, novel systems must be
developed that can overcome the intracellular barriers to effective nucleic acid delivery.
4.2. Targeting ligands
One method of targeting is via the incorporation of targeting ligands that bind to cell-sur‐
face receptors. This approach is dependent upon possession of the knowledge of which re‐
ceptor or combinations of receptors are hyperactivated on the cancer cell surface. One such
example is the asialoglycoprotein receptor (ASGPr) which, although present on the surface
of normal hepatocytes, is overexpressed in hepatocarcinoma cells. The ligand asialofetuin
has been attached to a novel lipopolymeric nanoparticle to deliver the immunostimulatory
IL-12 cytokine in the treatment of hepatocellular carcinoma. Following intratumoural ad‐
ministration of the targeted nanoparticles, the authors showed survival in 75% of mice treat‐
ed with targeted nanoparticles compared to 38% in the non-targeted nanoparticles. This
indicates that the presence of the ASGPr targeting ligand improves intracellular internaliza‐
tion via receptor-mediated endocytosis. Following systemic delivery of either nanoparticle
type, luciferase expression in the liver and lungs was assessed. Luciferase expression was
10-fold higher in the livers of those mice that received targeted nanoparticles. However,
there was also gene expression in the lung with no significant differences between targeted
and non-targeted nanoparticles which indicates that further formulations may be necessary,
and that evaluation of gene expression in all the organs is necessary to confirm appropriate
targeting [123].
Another useful targeting ligand for cancer gene therapy is transferrin. Transferrin is overex‐
pressed in many malignancies including breast, bladder and lung [124-126]. The differential
expression of the transferrin receptor and its extracellular location make it an ideal target for
systemic targeting. Systemic delivery of transferrin covalently linked to polyethylenimine
has not only shown effective tumour targeting in vivo, but it can also shield the positive
charge of the nanoparticles [127]. Studies by Kircheis showed that a lower molecular weight
of PEI was less toxic and that the incorporation of 25% of the negatively charged lipophilic
transferrin ligand gave an almost neutral zeta potential with a significant reduction in ag‐
gregation of erythrocytes. In vivo this translated into lower toxicity, one log greater gene ex‐
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pression than transferrin-free nanoparticles and a ‘shielding’ effect to bypass organs such as
the lung and target the tumour [127].
Identification of overexpressed receptors can also lead to the development tumour target‐
ing  peptides.  Using  phage  display  methods,  the  T7  peptide  (HAIYPRH)  was  identified
and shown to specifically bind to the human transferrin receptor, with competitive stud‐
ies indicating that T7 bound at a different site to transferrin [128]. This T7 peptide has re‐
cently been utilised for targeted co-delivery of the chemotherapy drug doxorubicin (DOX)
together with the human TRAIL gene (Tumour necrosis factor Related Apoptosis-Induc‐
ing  Ligand)  to  target  gliomas  which  are  known to  overexpress  the  transferrin  receptor
[129]. DOX was conjugated with a pH linker (for endosomal release) to T7-modified den‐
digraft poly-L-Lysine dendrimers which then condensed the pORF-hTRAIL DNA [129]. In
vitro and in vivo evaluations revealed targeting via the transferrin receptor and accumula‐
tion of the nanoparticles in gliomas following systemic delivery with a synergistic effect.
In addition, the targeted T7 nanoparticles induced much less off site toxicity while induc‐
ing a significant anti-tumour effect [129].
Other targeting ligands of note include the epidermal growth factor receptor that is upregu‐
lated in a number of solid tumours such as breast, prostate, colorectal, and ovarian [130]. Al‐
though some anti-cancer strategies are designed to prevent EGFR activation via small
molecule inhibitors such as gefitinib or antibodies such as Cetuximab [131], an alternative is
to exploit the differential expression of EGFR. Thiol functionalisation to attach the mouse
EGF ligand to PEGylated branched PEI (25 kDa) has shown excellent in vivo targeting to
hepatocellular carcinoma. Biodistribution studies illustrate quite clearly that there is signifi‐
cantly more expression of the luciferase gene in both Huh-7 and HepG2 HCC tumours com‐
pared to other organs following intravenous injection of the complexes [132]. The authors
also found that any distribution of the DNA to the liver was exclusively in the Kupffer cells
and not the epithelial cells, indicative of degradation.
The EGF-PEG-PEI system has also been used to selectively deliver synthetic double strand‐
ed RNA (poly IC) [133]. Typically dsRNA is found in virally infected cells and an associated
response involves the induction of apoptosis and recruitment of inflammatory cytokines
[134,135]. Delivery of poly IC with PEI25-PEG-EGF killed up to 85% of EGFR-over-express‐
ing glioblastoma multiform cells in vitro via apoptosis after 1 hour [133]. This cytotoxic effect
was significantly enhanced when the PEI was partially replaced with a PEI-Mellitin conju‐
gate, which improved endosomal disruption, enabling greater delivery of the dsRNA to the
cytoplasm. In addition, the intratumoural delivery of (poly IC) PEI-PEG-EGF+PEI-Mel com‐
plexes completely eradicated the intracranial tumours for more than 1 year [133]. Further
studies have revealed that with further formulation of the delivery vehicle (Linear PEI-PEG
2 kDa-EGF), systemic delivery of poly IC can significantly reduce A431 tumour growth in
vivo [136]. Similar to transferrin, polypeptides for EGFR have been isolated and used effec‐
tively in cancer gene therapy. Phage display revealed an 11 amino acid sequence (YHWY‐
GYTPQNVI) termed GE11 that has shown specificity to the EGFR after both in vitro and in
vivo studies [137]. Furthermore, when the GE11 peptide was conjugated to PEI and com‐
pared with EGF-PEI, it was found that the latter enhanced mitogenic activity, which is clear‐
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ly undesirable in the cancer environment. The authors indicate that due to this lack of
mitogenic activity, the GE11 ligand is safer in vivo, and delivery of the luciferase gene intra‐
venously revealed an 18-fold increase in luciferase expression in human hepatoma
SMMC-7721 tumours compared to non-targeted PEI [137].
The fibronectin attachment protein of mycobacterium has also been utilised as a targeting
ligand to the fibronectin molecule on epithelial cell membranes [138]. The Fab receptor was
conjugated to chitosan-DNA nanoparticles and delivered via an air jet nebuliser to enhance
gene expression in the lung epithelium. Again using the luciferase reporter gene, studies re‐
vealed that there was a 16-fold increase in gene expression over the non-targeted chitosan
nanoparticles [138]. Another example of exploitation of differential expression is in glioma
brain capillary endothelial cells that have an upregulation of the lipoprotein receptor-related
protein-1. The angiopep-2 peptide ligand (TFFYGGSRGKRNNFKTEEY) has been success‐
fully conjugated to a polyamidoaminedendrimer (PAMAM) with a PEG spacer and studies
showed that cellular uptake of the nanoparticles was targeting ligand dose-dependent, and
that targeting to the brain was achieved following intravenous delivery [139]. The angiopep
targeting system has also been utilised to achieve a therapeutic efficacy in the delivery of
PAMAM-PEG-Angiopep/pORF-TRAIL to glial tumours [140]. The administration of these
modified nanoparticles yielded an average survival time of 69 days compared to 30 days in
the parental PAMAM-PEG/pORF-TRAIL nanoparticle-receiving mice [140].
There are of course numerous examples of systemic targeted delivery employing such li‐
gands. The message that is apparent from all of these studies is that if there is enough infor‐
mation on the expression of a certain receptor, then the incorporation of its targeting ligand
into cationic non-viral systems can significantly enhance tumour-targeted accumulation of
the nucleic acid.
4.3. Affibody targeting
Affibodies are small stable alpha helical proteins that lack disulphide bonds, have a low mo‐
lecular weight and are essentially designed to mimic the action of antibodies. An original
affibody protein scaffold is used as a template from which combinatorial phage libraries can
be generated and subsequently ligand-specific affibodies can be selected from using phage
display technology. Such protein scaffolds have been generated from bacterial surface recep‐
tors such as the IgG binding domains of staphylococcal protein A (SPA). The 58 amino acid
Z domain from staphylococcal protein A (SPA) is one such scaffold that has been used as a
template for ligand specific affibodies [141,142].
With respect to cancer targeting, high affinity affibodies have been generated for Human Epi‐
dermal Growth Factor Receptor 2 [143], Epidermal Growth Factor Receptor [144], Insulin-like
Growth Factor-1 Receptor [145] and Platelet Derived Growth Factor Receptor β [146]. Using
radio-labelling, all of the affibodies have been shown to accumulate in tumours in vivo with an
impressive level of specificity following systemic delivery. The affinity of the affibodies is an
important factor and ideally should be in the nanomolar range for effective targeting. For ex‐
ample, the affinity levels of affibody ZHER2:4 are 50 nmol/L [147] whereas using a one step affin‐
ity maturation process, Orlova and colleagues were able to generate the ZHER2:342  affibody
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which has an affinity level of 22 pmol/L [143]. The increased affinity translated into a 4-fold in‐
crease in tumour uptake of ZHER2:342 four hours post-injection with clear contrast in imaging
and stability at least up to 24 h post-injection. With respect to the first generation EGFR affi‐
bodies, the affinity was in the 150 nM range [148] which is sub optimal for effective systemic
targeting. A similar one step maturation procedure for the EGFR affibody showed that affini‐
ty could be significantly improved whereby ZEGFR1907 had a Kd of 5.4 nM. Furthermore, there
was significant uptake of the indium-111-labeled affibody ZEGFR1907  in A431 tumours and
EGFR-expressing organs in vivo compared to the non-EGFR-affibodyZtaq [144].
Translational applications of these 2nd generation affibodies to date include therapeutic tools
for diagnostic and imaging purposes to aid in the identification of molecular drug targets
and for the stratification of cancer patient populations. However these highly stable, selec‐
tive proteins are undoubtedly going to have a huge role in the advancement of targeted
non-viral systems in cancer gene therapy. Recently a peptide chimera was designed that
consisted of the cell penetrating peptide TAT (T), the DNA condensing motif Mu and the
HER2 affibody (AF). The position of the AF was critical to ensure targeting functionality
given that the affibody must be able to fold properly. Prior to synthesis, ITASSER software
was employed to predict functionality based upon peptide design with a linker between
TAT-MU and AF that was helical and should therefore ensure stability of the domains [149].
Studies with the purified recombinant TAT-Mu-AF showed that this ternary complex could
condense DNA, confer protection from degradation by DNase I and offer stability in serum
[150]. Using GFP DNA complexed at a 1:8:2 ratio, there was little uptake of the complexes in
the HER2-null MDA-MB-231 cell line and green fluorescence in the HER2-expressing MDA-
MB-453, SK-OV-3 and SK-BR-3 cell lines that was proportional to HER2 receptor density.
Furthermore, the complexes were non-toxic and functional when injected intra-tumourally
into the HER2 positive MDA-MB-453 breast tumours in vivo [150]. Unfortunately these ter‐
nary complexes as yet have not been administered intravenously, which is the ultimate test
of functionality, given the range of extracellular barriers previously discussed. Nevertheless,
this ternary peptide system holds a lot of promise in the next generation of targeted peptide/
protein delivery systems for non-viral gene therapy.
PEGylated liposomes have also been synthesised conjugated to the ZEGFR:1907 affibody with a
cysteine residue at the C-terminus to form sterically stabilised affibody liposomes (SAL)
[151]. Although the SAL system was loaded with the drug mitoxantrone (MTO), other mac‐
romolecules such as nucleic acids could be applied to this system. The MTO-SAL nanoparti‐
cles were tested for cytotoxicity on EGFR-expressing A431 and MDA-MB-468 cell lines with
MCF-7 as a negative control. Results indicated that the MTO-SAL nanoparticles had no ef‐
fect on the viability of the EGFR-negative MCF-7 cell line (IC50 value > 100 µM, compared
with an IC50 of 18 µm for MTO alone), while the EGFR-expressing A431 (2.8 µM) and
MDA-MB-468 (6.8 µM) cell lines were as sensitive to MTO-SAL nanoparticles as they were
to MTO only (IC50 1.3 µM and 3 µM respectively) [151]. Taken together, these data suggest
that SAL specifically delivered its MTO payload to the EGFR-expressing cells, and that
EGFR-null cells were protected from MTO-induced cytotoxicity by the SAL vehicle. These
studies illustrate that cysteine-modified affibodies can be targeting ligands on liposomal de‐
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livery vehicles. Furthermore, by ensuring that receptor-mediated endocytosis occurs via the
affibodies, a protective effect is conferred on non-expressing receptor tissue which is highly
attractive for the delivery of cytotoxic nucleic acids.
Another example of the use of the ZHER2:342 affibody [143] is in a multifunctional biopolymer
system that comprises several discrete functions [152]. This system consists of a fusogenic
peptide (FP) sequence H5WYG [153], a DNA-condensing and endosomolytic domain (DCE)
with repeating sequences of arginine and histidine, a M9 nuclear localization domain (NLS)
[154] and a C-terminal ZHER2:342 affibody [143]. What is particularly striking about this deliv‐
ery system is that the authors have designed it taking into account all of the intracellular
barriers, and with the use of discrete motifs, have attempted to overcome each hurdle to suc‐
cessful gene delivery. Engineered within this delivery system is also cathepsin D enzyme
substrate (CS) to enable cleavage of the targeting motif from the rest of the vector in late en‐
dosomes [152]. The DNA sequence for FP-(DCE)3-NLS-CS-TM was cloned into an inducible
expression system and the recombinant biopolymer was expressed and extracted using af‐
finity and size exclusion chromatography [152]. The functionality of each discrete motif was
proven and competitive inhibitor binding and transfection studies clearly indicated that the
affibody ensured receptor-mediated endocytosis in vitro [152]. Transfection efficiency of 21%
was achieved in the SKOV-3 HER2-expressing cell line, while efficiencies of only 0.1 and 2%
were achieved in the non-expressing PC-3 and MDA-MB-231 prostate and breast cancer cell
lines, respectively. In vivo delivery and evaluation of the immune response are critical for
the future development of such smart biopolymer systems. Nevertheless, this study illus‐
trates that high affinity affibodies can be functional in recombinant delivery vectors, thus
enabling receptor targeting to occur.
4.4. Transcriptional targeting
Of course it may not be necessary to have a targeted delivery system to achieve expression of a
desired gene in a particular tissue. Many tumours have a differential expression of a particu‐
lar transcription factor that can be exploited and used to restrict gene expression to a particu‐
lar site. Several promoters that are either tissue- or tumour-specific have been developed that
can circumvent the issues surrounding targeting delivery systems. For example the differen‐
tial expression in telomerase activity between tumour and normal tissue together with the
identification of the minimal components necessary for telomerase activity has enabled the
use of the human telomerase reverse transcriptase and the template containing telomerase
(hTERT and hTER) promoters to control gene expression. Studies by Dufès et al showed that
systemic delivery of polypropylenimedendrimers complexed with a TNFalpha-expressing
plasmid under the control of hTER and hTERT gave regression of solid carcinomas in xeno‐
grafts with 100% survival with no obvious signs of toxicity [155]. The hTERT promoter has al‐
so been used in a dual reporter system with the human alpha fetoprotein (hAFP) promoter to
drive expression of MicroRNA-26a (MiR-26a), a known tumour suppressor downregulated in
hepatocellular  carcinoma (HCC) [156].  The dual  promoter system significantly increased
MiR-26a expression and reduced viability in vitro and in vivo compared to single promoter or
constitutively driven MiR-26a constructs in the HCC cell lines [156].
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Insulin-like Growth Factor 2 (IGF2) is involved in cellular proliferation and differentiation,
but is also overexpressed in a variety of tumours such as bladder carcinoma [157]. IGF2 has
a total of four promoters with P3 and P4 promoters responsible for IGF2 expression during
foetal and tumour development [158]. P3 and P4 have been utilized to drive expression of
the cytotoxic Diphtheria Toxin A gene both as a single promoter system and a dual promot‐
er construct termed P4-DTA-P3-DTA [159]. Part of the rationale for this was related to the
differential activation of both P3 and P4 regulatory sequences in human tumours, so a dual
system would ensure induction of DTA in a larger population of tumours. Using PEI as the
delivery vehicle, bladder carcinoma studies have revealed that P4-DTA-P3-DTA was superi‐
or in vitro and in vivo in both heterotropic and orthotopic bladder tumour models [159]. Sim‐
ilar studies have also been performed in glioma models utilising the cancer-specific H19
promoter in tandem with the P4-IGF2 promoter to selectively control DTA expression [160].
These dual systems have to-date focused on accessible tumours where intratumoural injec‐
tion would suffice, but only systemic delivery of such systems will fully validate the tran‐
scriptional control afforded by these promoters.
Many cancers have the propensity to metastasize to bone, and such tumours acquire osteomi‐
metic characteristics in order to adapt and thrive in the local bone environment. Disseminat‐
ed bone deposits are resistant to conventional therapies and are particularly difficult to target.
Osteocalcin is the most abundant noncollagenous bone matrix protein and is involved in the
regulation of bone formation and resorption [161-163]. Osteocalcin is also overe-xpressed in a
range of cancers including ovarian, lung, brain, breast and prostate [164-166]. The transcrip‐
tion factor largely responsible for activating the osteocalcin promoter is the master transcrip‐
tion factor RUNX2. RUNX2 is also highly expressed in tumours that metastasise to bone, and
therefore widespread activation of the human osteocalcin (hOC) promoter should be ach‐
ieved, regardless of the heterogeneous tumour microenvironment. The hOC promoter has
been utilized to drive inducible nitric oxide synthase (iNOS) expression [167,168]. Commer‐
cially available liposomes were used as a delivery vehicle for the hOC-iNOS construct. This
resulted in exquisite specificity for androgen-independent prostate cancer cells in vitro, cou‐
pled with cytotoxicity comparable to that of constitutively expressed iNOS. In vivo data also
confirmed the potency of hOC-iNOS gene therapy in a mouse xenograft model of human
prostate (PC-3) cancer. Multiple intra-tumoural injections slowed tumour growth dramatical‐
ly and led to some complete responses. On average, tumour growth was delayed by 59 days
compared to vector only controls. This data from these studies supports the premise that tu‐
mour-specific promoters can effectively drive iNOS monotherapy giving long term tumour
control. Future work within this group is now focused on systemic delivery of hOC-iNOS
gene therapy. The hOC promoter has also been delivered systemically to control expression of
TK in a replication-defective adenovirus (Ad-hOC-TK) and early viral genes in a replication
competent adenovirus (Ad-hOC-E1) [169]. The authors found that vitamins C and D3 signifi‐
cantly increased the activity of the hOC promoter and that triple therapy with Ad-hOC-E1, vi‐
tamin D3 and vitamin C resulted in complete regression in 38% of renal cell carcinomas in vivo
following a single intravenous injection [169].
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Targeting to a desired tissue is quite often the stumbling block to systemic cancer gene ther‐
apy. For the delivery of DNA, targeting can be achieved through the use of promoter se‐
quences. The success of this method of targeting is reliant upon prior knowledge of a
difference in transcription factor expression between the target and normal tissue. A deliv‐
ery system could therefore be designed to condense the DNA, traverse cell membranes, dis‐
rupt endosomes and actively transport the payload to the nucleus without the added
biophysical complications of having an external targeting motif. Such a delivery system
would in theory deliver the DNA to all tissue, but the DNA would only be transcribed and
translated where the desired transcription factor is present, namely the target tissue.
5. Multifunctional delivery
An understanding of the key biological barriers is critical to the success of a multifunctional
delivery vehicle. Perhaps one of the most multifaceted delivery vehicles is the Multifunc‐
tional Envelope-type Nano Device MEND system [170]. The authors describe this as a ‘pro‐
grammed packaging’ system whereby each part of the system is designed to carry out a
specific function in a time-controlled manner. In this system the nucleic acid is condensed
with a cationic polymer, wrapped in a lipid envelope which is then functionalised with PEG
or other targeting ligands [170]. It is quite clear that PEGylated MEND did have a longer
circulation time and was not rapidly cleared from the liver. These are ideal extracellular de‐
livery characteristics, but unfortunately this translated into a much lower gene expression.
Therefore circumvention of the ‘PEG dilemma’ could be achieved via the attachment of tar‐
geting ligands to receptors that are known to be over-expressed on tumour cells coupled
with the attachment of a cleavable PEG that exploits either intracellular or tumour-specific
characteristics. Figure 2 contains a representation of a MEND that highlights some of the nu‐
cleic acids that have been delivered and functionalisation strategies that have been used.
The avoidance of an immune response to non-viral strategies can also be greatly improved
by use of MENDs as delivery devices. Delivery of pDNA to mice by a MEND resulted in
differential expression of almost 1600 genes; PEGylation of the MEND reversed the altered
expression of many of these genes. Gene Ontology analysis revealed that in general, the up‐
regulated genes were associated with “immune response,” “response to biotic stimulus,”
“defence response,” and related processes. The expression of IL-6, but not IFNα (commonly
activated cytokines, as discussed above), were lower in the PEGylated MEND group com‐
pared with the non-PEGylated [171]. PEGylation has been shown to limit endosomal escape
of gene delivery complexes [172]; inclusion of GALA in the MEND facilitated endosomal es‐
cape, and diminished the previously elevated IFNα levels [171]. A MEND functionalised
with a PEG-peptide-DOPE conjugate (PPD) was stable in the systemic circulation after intra‐
venous delivery (thereby benefiting from PEG’s stabilising characteristic), while it also po‐
tently delivered its pDNA cargo to HT1080 fibrosarcoma cells (MMP-rich), but not to
HEK293 human embryonic kidney cells (MMP-deficient), thereby avoiding PEG’s limiting
characteristic [173]. Cleavage of PEG by MMPs facilitates the targeting of tumour tissues
which are high in MMPs.
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Figure 2. Simplified amalgamation of multifunctional envelope-type nano devices (MENDs) that have been employed
for non-viral gene therapy development. pDNA cargoes encoding proteins such as luciferase [173-175] and GFP [176]
have been delivered, as well as siRNA targeting luciferase [177,178] and ACTB [179]. MEND polycations are generally
PLL [174,178] or protamine [173,175,176]. Lipid envelopes usually comprise DOTAP, DOPE and cholesterol
[177,179,180], but can also include CHEMS [174,178]. Tetra-lamellar MEND envelopes comprise DOPE/cholesterol in‐
ner and DOPE/phosphatidic acid outer layers [176]. Functionalisation of MENDS with GALA/short GALA [179], STR-R8
[174,176,178], PEG and MMP-cleavable PEG [170,173,177] and sugar-lipid conjugates [175] have all been reported.
Based on [181].
The fundamental limitation associated with non-viral gene therapies is their low transfec‐
tion ability, compared with viral systems [1]. pDNA condensed using poly-L-lysine and in‐
corporated into a MEND that comprised DOPE, cholesterylhemisuccinate and an octa-
arginine (R8) peptide (DOPE/CHEMS/STR-R8) transfected HeLa and A549 cells as
efficiently as an adenovirus vector. Moreover, the parity of transfection efficiency was ach‐
ieved without negatively impacting cell viability, as was the case with adenovirus and Lipo‐
fectamine™, and evoked its therapeutic benefit following transdermal delivery in mice
[181]. The R8 peptide has been used similarly to deliver proteins directly to cells [182].
A tetra-lamellar MEND (T-MEND) was nano-engineered that envelops the cationically-con‐
densed pDNA in distinct functional layers to target the distinct barrier membranes faced by
a nanoparticle. The pDNA-containing core was wrapped in a nucleus-fusogenic lipid mem‐
brane, which was in turn wrapped in an endosome-fusogenic lipid membrane that was
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modified with a high density of octa-arginine. Upon endocytosis into the cell, the T-MEND’s
outermost membrane fuses with the endosomal membrane, releasing the nucleus-fusogenic
lipid membrane-bound pDNA core from the endosome into the cytoplasm. The nuclear
membrane is then overcome by fusion of the inner nucleus-fusogenic lipid membrane with
the nuclear membrane, facilitating transport of the pDNA core into the nucleus. Despite the
complexity of the particles, the fully-formed T-MEND produced particles of 163 nm diame‐
ter, and zeta potential of 54.5mV. Unsurprisingly, the T-MEND facilitated impressive pLuci‐
ferase delivery in vitro [176]. This exciting T-MEND was further functionalised by addition
of fusogenic KALA to the outer and inner membranes, which improved transfection 20-fold
[183]. To the authors' knowledge, systemic delivery of multi-layered MENDs is yet to be re‐
ported. Caution must be advised, as promising in vitro findings do not always translate into
impressive in vivo developments.
6. Conclusion
It is apparent that the field of non-viral gene delivery is making significant progress in the
quest for the ideal gene delivery vehicle. What is also evident is that the most successful sys‐
tems are designed to overcome many biological barriers and as a consequence the tradition‐
al single function systems are now rendered obsolete. Viruses are nature’s perfect delivery
vehicle and provide the inspiration to many non-viral gene therapy researchers in the de‐
sign of state of the art multi-faceted vehicles. Through a greater understanding and appreci‐
ation of the biological barriers to systemic gene delivery, non- viral gene therapy researchers
are on the cusp of creating a variety of highly efficient vehicles that will revolutionise cancer
gene therapy.
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